Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aniline SCHEMBL22169159 | 0.92 | ALDH1A1 (0.42) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL1134126 | 0.91 | MCHR1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL8785098 | 0.90 | MCHR1 (0.55) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL358791 | 0.90 | ALDH1A1 (0.41) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL29527476 | 0.90 | MCHR1 (0.53) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL3799059 | 0.90 | MCHR1 (0.53) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL3798831 | 0.86 | KAT2B (0.53) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL2334040 | 0.86 | HRH1 (0.62) | HRH1HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9505634 | 0.86 | HRH1 (0.41) | ALDH1A1ADRA2BPTGS1TDP1HRH1 | |
| SCHEMBL28418035 | 0.83 | HTR1A (0.50) | ADRA2BHRH1MCHR1HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977942-A | Quinazolinone derivative for inducing iron death as well as synthesis method and application thereof | 西安交通大学 | 2025-05-13 | — | — | CN | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3954684-A1 | PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021257857-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. | 2019-08-01 | — | — | US | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-6689782-B2 | 3-PIPERAZINYL-2-DIARYLUREA-QUINAZOLINONE DERIVATIVES; POTENTIATORS OF ANTIFUNGAL AGENTS | ESSENTIAL THERAPEUTICS, INC. | 2004-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 2897/4885ADRA2B 4445/4885PTGS1 878/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885ADRA2B 926/4885PTGS1 1269/4885 |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | ALDH1A1 2897/4885ADRA2B 4445/4885PTGS1 878/4885 |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | NR1H4, FXR1, FXR2 | ALDH1A1 1318/4885ADRA2B 578/4885PTGS1 847/4885 |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | ALDH1A1 2172/4885ADRA2B 845/4885PTGS1 1351/4885 |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | NR1H4, FXR1, FXR2 | ALDH1A1 1318/4885ADRA2B 578/4885PTGS1 847/4885 |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ALDH1A1 2172/4885ADRA2B 845/4885PTGS1 1351/4885 |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885ADRA2B 926/4885PTGS1 1269/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885ADRA2B 926/4885PTGS1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.